Microspheres of pancreatic enzymes with high stability and production method thereof
The present invention refers to new microspheres including pancreatic enzymes, pharmaceutical compositions containing them, and a process to obtain them. The process here described doesn't involve the use of solvents and proves to be remarkably shorter and efficient than the producing methods of the prior arts. The microspheres obtained, including one or more pancreatic enzymes, one or more hydrophilic low-melting polymers and eventual excipients, have an high enzymatic activity, bio-availability and stability.
1. Microspheres comprising one or more pancreatic enzymes, one or more hydrophilic low melting polymers, and optionally excipients, the ratio between said one or more pancreatic enzymes and said one or more hydrophilic low melting polymers is between 4:1 and 1:1, said microspheres having diameter comprised between 10 μm and 1500 μm and enzymatic titer equal to or higher than 90% of the titer of the solid mixture of their components.
2. Microspheres according to claim 1 , having diameter comprised between 100 μm and 800 μm and enzymatic titer equal to or higher than 95% of the titer of the solid mixture of their components.
3. Microspheres according to claim 1 , where said hydrophilic polymer has melting point between 20° C. and 90° C.
4. Microspheres according to claim 1 , where said hydrophilic polymer has melting point between 30° C. and 70° C.
5. Microspheres according to claim 1 , comprising between 15% and 40% w/w of said hydrophilic polymer and between 60% and 85% w/w of said pancreatic enzymes.
6. Microspheres according to claim 1 , where said hydrophilic polymer is selected from polyethylene glycol, polyoxyethylene, copolymers of polyoxyethylene and polyoxypropylene or mixtures thereof.
7. A pharmaceutical composition comprising microspheres of claim 1 , and pharmaceutically acceptable excipients, wherein the composition is optionally coated with a polymeric film.
8. The composition of claim 7 in form of powder, pellets, hard or soft gelatine capsules, tablets, microtablets, solutions or suspensions.
9. The composition of claim 7 , wherein one or more pancreatic enzymes is present in weight rate between about 40% and about 99% and one or more hydrophilic low melting polymers is present in weight rate between about 1% and 60%.
10. A dosage form comprising the pharmaceutical composition of claim 7 .
11. The dosage form of claim 10 , wherein one or more pancreatic enzymes is present in weight rate between about 40% and about 99% and one or more hydrophilic low melting polymers is present in weight rate between about 1% and 60%.
12. A method of treating a disease condition, comprising administering the composition of claim 7 to a patient in need thereof.